Seelos Therapeutics, Inc. (SEELQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
+0.0001 (9,900.00%)
Jan 30, 2026, 1:20 PM EST
Seelos Therapeutics Employees
Seelos Therapeutics had 8 employees as of June 30, 2024. The number of employees decreased by 8 or -50.00% compared to the same quarter last year.
Employees
8
Change
-8
Growth
-50.00%
Revenue / Employee
$251,750
Profits / Employee
$511,375
Market Cap
136.00
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2024 | 8 | -8 | -50.00% | 8 | 0 |
| Mar 31, 2024 | 10 | -6 | -37.50% | 10 | 0 |
| Dec 31, 2023 | 16 | 0 | - | 15 | 1 |
| Sep 30, 2023 | 16 | 0 | - | 16 | 0 |
| Jun 30, 2023 | 16 | 1 | 6.67% | 16 | 0 |
| Mar 31, 2023 | 16 | 0 | - | 16 | 0 |
| Dec 31, 2022 | 16 | 0 | - | 15 | 1 |
| Sep 30, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Jun 30, 2022 | 15 | 1 | 7.14% | 15 | 0 |
| Mar 31, 2022 | 16 | 3 | 23.08% | 16 | 0 |
| Dec 31, 2021 | 16 | 6 | 60.00% | 15 | 1 |
| Sep 30, 2021 | 15 | 7 | 87.50% | 15 | 0 |
| Jun 30, 2021 | 14 | 6 | 75.00% | 14 | 0 |
| Mar 31, 2021 | 13 | 7 | 116.67% | 13 | 0 |
| Dec 31, 2020 | 10 | 4 | 66.67% | 9 | 1 |
| Sep 30, 2020 | 8 | 2 | 33.33% | 8 | 0 |
| Jun 30, 2020 | 8 | 2 | 33.33% | 8 | 0 |
| Mar 31, 2020 | 6 | 1 | 20.00% | 6 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Seelos Therapeutics News
- 1 year ago - Seelos Announces Second Postponement of its Annual Meeting of Stockholders - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - PRNewsWire
- 1 year ago - Seelos Announces Postponement of its Annual Meeting of Stockholders - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces 1-for-16 Reverse Stock Split - PRNewsWire
- 1 year ago - Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces 1-for-8 Reverse Stock Split - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations - PRNewsWire